251 related articles for article (PubMed ID: 36670359)
1. Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial.
Kamal A; Ghazy RM; Sherief D; Ismail A; Ellakany WI
BMC Infect Dis; 2023 Jan; 23(1):36. PubMed ID: 36670359
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients with
Mokhtare M; Nikkhah M; Behnam B; Agah S; Bahardoust M; Masoodi M; Faghihi A
Indian J Pharmacol; 2020; 52(4):266-271. PubMed ID: 33078727
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
4. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
Chen MJ; Chen PY; Fang YJ; Bair MJ; Chen CC; Chen CC; Yang TH; Lee JY; Yu CC; Kuo CC; Chiu MC; Chou CK; Chen CY; Hu WH; Tsai MH; Hsu YC; Shun CT; Luo JC; Lin JT; El-Omar EM; Wu MS; Liou JM;
Lancet Gastroenterol Hepatol; 2023 Jul; 8(7):623-634. PubMed ID: 37178702
[TBL] [Abstract][Full Text] [Related]
5. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
6. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
7. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase iiib trial.
Ladrón-de-Guevara L; Bornstein-Quevedo L; González-Huezo S; Castañeda-Romero B; Costa FG; di Silvio-López M
Rev Gastroenterol Mex (Engl Ed); 2019; 84(3):274-283. PubMed ID: 30060902
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
[TBL] [Abstract][Full Text] [Related]
10. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
Lee H; Hong SN; Min BH; Lee JH; Rhee PL; Lee YC; Kim JJ
Dig Liver Dis; 2015 Feb; 47(2):114-8. PubMed ID: 25467826
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital.
Dib J; Alvarez B; Mendez L; Cruz ME
Arab J Gastroenterol; 2013 Sep; 14(3):123-5. PubMed ID: 24206741
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial.
Lu K; Lang C; Zou X; Zang L; Sang W; Feng Q; Mu Y; Liu L; Xu C; Zhao J
Trials; 2023 Jun; 24(1):413. PubMed ID: 37337241
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.
Alhalabi M; Alassi MW; Alaa Eddin K; Cheha K
BMC Infect Dis; 2021 Jul; 21(1):642. PubMed ID: 34218802
[TBL] [Abstract][Full Text] [Related]
15. Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial.
Song Z; Suo B; Tian X; Ren X; Xue Y; Niu Z; Zhou L
Dig Liver Dis; 2023 May; 55(5):601-607. PubMed ID: 36646526
[TBL] [Abstract][Full Text] [Related]
16. Success of susceptibility-guided eradication of
Wang YM; Chen MY; Chen J; Zhang XH; Feng Y; Han YX; Li YL
World J Gastroenterol; 2024 Jan; 30(2):184-195. PubMed ID: 38312120
[TBL] [Abstract][Full Text] [Related]
17. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Rakici H; Ayaz T; Akdogan RA; Bedir R
Digestion; 2014; 90(4):261-4. PubMed ID: 25547786
[TBL] [Abstract][Full Text] [Related]
18. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
[TBL] [Abstract][Full Text] [Related]
19. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
20. Efficacy And Cost-Effectiveness, Comparison Of 7-Days Vonoprazan Versus 14-Days Esomeprazole Based Triple Therapies For Treating Helicobacter Pylori Infection In Pakistani Population: A Randomized Clinical Trial.
Waqar F; Noor M; Farhat K; Ali S; Haider E; Fatima Gillani SF
J Ayub Med Coll Abbottabad; 2023; 35(Suppl 1)(4):S746-S751. PubMed ID: 38406904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]